Indication: Gynecologic Cancer
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Sub-indication: Ovarian, Fallopian tube
Principal Investigator: Mary Gordinier, M.D.Norton Cancer Institute
Sponsor: ImmunoGen, Inc.
Email for more information: GYN-NCIResearch@nortonhealthcare.org